Science Abstracts
Selective dopamine D
3 receptor antagonists. A decade of progress: 1997 – 2007
August 2008
August 2008
Authors : Fabrizio Micheli1 , Christian Heidbreder2
Affliation :
1GlaxoSmithKline SPA, Neurosciences Centre of Excellence for Drug Discovery, Department of Medicinal Chemistry, Via A Fleming 4, 37135 Verona, Italy ; ; Fabrizio.E.Micheli@gsk.com
2Philip Morris USA, Sensory Research, Centre for Research and Technology, 601 East Jackson Street, Richmond, VA 23261, USA Christian.Heidbreder@pmusa.com
DOI : 10.1517/13543776.18.8.821
Published in : Expert Opin. Ther. Patents Volume 18 Issue 8 2008 pages 821 840
Subject: Reviews
Keywords: 7TM , addiction , D 3 , dopamine , impulse control disorders , receptor , schizophrenia , selective antagonist
Abstract
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: IOM focus on affordable 'essential' benefits expected to stir debate on drug prices
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- AstraZeneca to take $381.5 million charge after two major trial failures
- First Phase III signs positive for cariprazine in bipolar mania
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
